Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | FNTA | P49354 | 1/20 | 0.48 |
| ▸ | FNTB | P49356 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15452568 | 0.92 | RXFP1 (0.67) | RXFP1MAPTHTTKMT2AFNTA | |
| SCHEMBL9937249 | 0.89 | MAPT (0.53) | RXFP1MAPTHTTKMT2AMEN1 | |
| SCHEMBL20164019 | 0.83 | RXFP1 (0.50) | RXFP1MAPTHTTKMT2AMEN1 | |
| SCHEMBL15452564 | 0.82 | RXFP1 (0.73) | RXFP1MAPTKMT2AMEN1ALDH1A1 | |
| SCHEMBL20164021 | 0.81 | KDM4E (0.49) | RXFP1MAPTHTTKMT2AMEN1 | |
| SCHEMBL9936723 | 0.80 | KDM4E (0.55) | RXFP1MAPTHTTKMT2AMEN1 | |
| SCHEMBL28222167 | 0.75 | HTT (0.52) | RXFP1MAPTHTTKMT2AFNTA | |
| SCHEMBL20347928 | 0.72 | MAPT (0.44) | RXFP1MAPTHTTKMT2AMEN1 | |
| SCHEMBL29882847 | 0.72 | MEN1 (0.45) | MAPTHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL19465228 | 0.71 | IDO1 (0.38) | RXFP1MAPTFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3304088-B1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | ELECTROPHORETICS LTD (GB) | 2025-07-30 | — | — | EP | claimed |
| EP-3304088-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | Electrophoretics Limited (GB) | 2018-04-11 | — | — | EP | claimed |
| US-9763947-B2 | Casein kinase 1delta (CK1delta) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-09-19 | — | — | US | claimed |
| WO-2016189163-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | ELECTROPHORETICS LIMITED (GB) | 2016-12-01 | — | — | WO | claimed |
| US-20160058745-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2016-03-03 | — | — | US | claimed |
| EP-2651404-B1 | CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS | ELECTROPHORETICS LTD (GB) | 2015-10-14 | — | — | EP | claimed |
| US-20260091025-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | ELECTROPHORETICS LIMITED (GB) | 2026-04-02 | — | — | US | disclosed |
| EP-4663754-A2 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | Electrophoretics Limited (GB) | 2025-12-17 | — | — | EP | disclosed |
| US-12419871-B2 | Biomolecules involved in Alzheimer's disease | ELECTROPHORETICS LIMITED (GB) | 2025-09-23 | — | — | US | disclosed |
| EP-3304088-B1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | ELECTROPHORETICS LTD (GB) | 2025-07-30 | — | — | EP | disclosed |
| US-20180140585-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | ELECTROPHORETICS LIMITED (GB) | 2018-05-24 | — | — | US | disclosed |
| EP-3304088-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | Electrophoretics Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-9789111-B2 | Casein kinase 1δ (CK 1δ) inhibitors | ELECTROPHORETICS LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2015-07-30 | — | — | US | disclosed |
| US-20140031547-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED | 2014-01-30 | — | — | US | disclosed |
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED | 2014-01-16 | — | — | US | disclosed |
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED | 2014-01-16 | — | — | US | disclosed |
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED | 2014-01-16 | — | — | US | disclosed |
| EP-2651404-A2 | CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS | Electrophoretics Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080727-A2 | CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS | ELECTROPHORETICS LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018540-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1G1, CSNK1A1, CSNK1D | RXFP1 2794/4885MAPT 56/4885PTK2B 302/4885 |
| US-20260091025-A1 | BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE | PYGB, PACSIN2, PPP3CA | RXFP1 3074/4885MAPT 25/4885PTK2B 482/4885 |
| US-20150209368-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1A1, CSNK1G1, CSNK1D | RXFP1 2663/4885MAPT 60/4885PTK2B 283/4885 |
| US-20140031547-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1G3 | RXFP1 3126/4885MAPT 24/4885PTK2B 344/4885 |
| US-20160058745-A1 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS | CSNK1A1, CSNK1G1, CSNK1D | RXFP1 2663/4885MAPT 60/4885PTK2B 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.